摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-2-羟甲基-3-甲基-1-苯基-2-吡唑啉-5-酮 | 10223-33-3

中文名称
4-2-羟甲基-3-甲基-1-苯基-2-吡唑啉-5-酮
中文别名
4-(2-羟基乙基)-3-甲基-1-苯基-2-吡唑啉-5-酮
英文名称
4-(2-Hydroxyethyl)-3-methyl-1-phenyl-2-pyrazolin-5-one
英文别名
4-(2-hydroxyethyl)-5-methyl-2-phenyl-4H-pyrazol-3-one
4-2-羟甲基-3-甲基-1-苯基-2-吡唑啉-5-酮化学式
CAS
10223-33-3
化学式
C12H14N2O2
mdl
MFCD00067790
分子量
218.25
InChiKey
AVOONTISHAAFGN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    90-92 °C(Solv: ethyl acetate (141-78-6))
  • 沸点:
    411.4±18.0 °C(Predicted)
  • 密度:
    1.22±0.1 g/cm3(Predicted)
  • 稳定性/保质期:

    遵照规格使用和储存则不会分解。

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    52.9
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933199090

SDS

SDS:6623c5c30ae19af32b0a0f0dd1391513
查看

反应信息

点击查看最新优质反应信息

文献信息

  • PREVENTIVE AND/OR THERAPEUTIC DRUGS FOR INFLAMMATORY INTESTINAL DISEASES
    申请人:Mitsubishi Pharma Corporation
    公开号:EP1553087A1
    公开(公告)日:2005-07-13
    The object of the present invention is to provide a medicament useful for preventing and/or treating inflammatory bowel disease. The present invention provides a medicament for preventing and/or treating inflammatory bowel disease which comprises as an active ingredient a pyrazolone derivative represented by the following formula (I) or a physiologically acceptable salt thereof, or a hydrate thereof or a solvate thereof: wherein R1 represents a hydrogen atom, an aryl group, an alkyl group, or an alkoxycarbonylalkyl group; R2 represents a hydrogen atom, an aryloxy group, an arylmercapto group, an alkyl group or a hydroxyalkyl group; or R1 and R2 are combined with each other to represent an alkylene group; and R3 represents a hydrogen atom, an alkyl group, a cycloalkyl group, a hydroxyalkyl group, a benzyl group, a naphthyl group, a phenyl group, or a phenyl group substituted with 1 to 3 substituents selected from the group consisting of an alkyl group, an alkoxy group, a hydroxyalkyl group, an alkoxycarbonyl group, an alkylmercapto group, an alkylamino group, a dialkylamino group, a halogen atom, a trifluoromethyl group, a carboxyl group, a cyano group, a hydroxyl group, a nitro group, an amino group and an acetamide group.
    本发明的目的是提供一种用于预防和/或治疗炎性肠病的药物。本发明提供了一种药物,用于预防和/或治疗炎性肠病,其包括以下式(I)所表示的吡唑酮衍生物作为活性成分,或其生理上可接受的盐,或其合物或溶剂化合物:其中R1表示氢原子,芳基,烷基或烷氧羰基烷基;R2表示氢原子,芳氧基,芳基,烷基或羟基烷基;或R1和R2结合在一起表示烷基;R3表示氢原子,烷基,环烷基,羟基烷基,苄基,基,苯基或苯基,其被1至3个取代基所取代,所述取代基被选自羟基烷基,烷氧基,羟基烷氧基,烷氧羰基,烷基,烷基基,二烷基基,卤素原子,三甲基基团,羧基,基,羟基,硝基,基和乙酰胺基。
  • AGENT FOR PREVENTING AND/OR TREATING OPHTHALMOLOGIC DISEASES
    申请人:MITSUBISHI TANABE PHARMA CORPORATION
    公开号:US20170273949A1
    公开(公告)日:2017-09-28
    It is an object of the present invention to provide a novel medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis. According to the present invention, provided is a medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis, which comprises, as an active ingredient, a pyrazolone derivative such as 3-methyl-1-phenyl-2-pyrazolin-5-one, or a physiologically acceptable salt thereof, or a hydrate thereof or a solvate thereof.
    本发明的目的是提供一种新型药物,用于预防和/或治疗由眼部血管生成引起的眼科疾病。根据本发明,提供了一种用于预防和/或治疗由眼部血管生成引起的眼科疾病的药物,其包括作为活性成分的吡唑酮衍生物,如3-甲基-1-苯基-2-吡唑啉-5-酮,或其生理上可接受的盐,或其合物或溶剂化物。
  • Medicament for prevention and/or therapy of arterial wall disorder
    申请人:——
    公开号:US20040254234A1
    公开(公告)日:2004-12-16
    An object of the present invention is to provide a medicament and method which is useful for prevention and/or therapy of arterial wall injury. According to the present invention, there is provided a method for prevention and/or therapy of arterial wall injury which comprises a step of administering the pyrazolone derivative represented by the following formula (I) or the physiologically acceptable salt thereof, or the hydrate or solvate thereof in a preventively or therapeutically effective amount to mammals including humans: 1 wherein R 1 represents a hydrogen atom, an aryl group, an alkyl group, or an alkoxycarbonylalkyl group; R 2 represents a hydrogen atom, an aryloxy group, an arylmercapto group, an alkyl group or a hydroxyalkyl group; or R 1 and R 2 are combined with each other to represent an alkylene group; and R 3 represents a hydrogen atom, an alkyl group, a cycloalkyl group, a hydroxyalkyl group, a benzyl group, a naphthyl group, a phenyl group, or a phenyl group substituted with 1 to 3 substituents selected from the group consisting of an alkyl group, an alkoxy group, a hydroxyalkyl group, an alkoxycarbonyl group, an alkylmercapto group, an alkylamino group, a dialkylamino group, a halogen atom, a trifluoromethyl group, a carboxyl group, a cyano group, a hydroxyl group, a nitro group, an amino group and an acetamide group.
    本发明的目的是提供一种药物和方法,用于预防和/或治疗动脉壁损伤。根据本发明,提供了一种预防和/或治疗动脉壁损伤的方法,包括向哺乳动物,包括人类,预防性或治疗性地给予以下式(I)所表示的吡唑酮衍生物或其生理上可接受的盐,或其合物或溶剂,以预防或治疗有效量:1其中R1表示氢原子,芳基,烷基或烷氧羰基烷基;R2表示氢原子,芳氧基,芳醇基,烷基或羟基烷基;或R1和R2结合在一起表示烷基;R3表示氢原子,烷基,环烷基,羟基烷基,苄基,基,苯基或苯基,其被1至3个取自羟基烷基,烷氧基,烷氧羰基基,烷基,烷基基,二烷基基,卤素原子,三甲基基,羧基,基,羟基,硝基,基和乙酰胺基的取代基所取代。
  • Drugs comprising combination of antithrombotic agent with pyrazolone derivative
    申请人:Yamada Keiichi
    公开号:US20050009896A1
    公开(公告)日:2005-01-13
    It is intended to provide drugs for treating and/or preventing ischemic diseases which are safe and have little side effects. Namely, drugs comprising a combination of an antithrombotic agent and a pyrazolone derivative defined in the description or its pharmaceutically acceptable salt.
    本发明旨在提供一种安全并且副作用小的药物,用于治疗和/或预防缺血性疾病。即,药物包括在说明书中定义的抗血栓药物和吡唑酮衍生物的组合或其药学上可接受的盐。
  • Methods of treating alzheimer's disease
    申请人:Nieman A. James
    公开号:US20060079533A1
    公开(公告)日:2006-04-13
    Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of 3,4-disubstituted piperidinyl compounds of formula (I) wherein the variables R 1 , R 2 , R 3 , R 4 , Q, W, X, Z, m, and n are defined herein.
    本发明公开了一种治疗阿尔茨海默病和其他疾病、抑制β-分泌酶酶和/或抑制哺乳动物中A beta肽沉积的方法,使用式(I)的3,4-二取代哌啶基化合物,其中变量R1、R2、R3、R4、Q、W、X、Z、m和n在此定义。
查看更多

同类化合物

(4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] 香豆素-6-羧酸 顺式-3a,5,6,6a-四氢-3-(1-甲基乙基)-4H-环戊二烯并[d]异恶唑 锌离子载体IV 钐(III) 离子载体 II 苯,1-(2E)-2-丁烯-1-基-2-氟- 苯,(2,2-二氟乙烯基)- 聚二硫二噻唑烷 缩胆囊肽9 绕丹酸钠 盐(1:?)5'-尿苷酸,钠 甲酰乙内脲 甲巯咪唑 甲基羟甲基油基噁唑啉 甲基5-羟基-3,5-二甲基-4,5-二氢-1H-吡唑-1-羧酸酯 甲基5-甲基-4,5-二氢-1H-吡唑-3-羧酸酯 甲基5-甲基-4,5-二氢-1H-吡唑-1-羧酸酯 甲基5-氰基-4,5-二氢-1,2-恶唑-3-羧酸酯 甲基5-乙炔基-4,5-二氢-1H-吡唑-3-羧酸酯 甲基5-(羟基甲基)-4,5-二氢-1,2-恶唑-3-羧酸酯 甲基4-甲基-5-氧代-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4-甲基-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4-乙炔基-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4,5-二氮杂螺[2.4]庚-5-烯-6-羧酸酯 甲基4,5-二氢-5-乙基-1H-吡唑-1-羧酸酯 甲基3-甲基-4,5-二氢-1,2-恶唑-4-羧酸酯 甲基(E)-3-[6-[1-羟基-1-(4-甲基苯基)-3-(1-吡咯烷基)丙基]-2-吡啶基]丙烯酰酸酯 甲基(5-氧代-4,5-二氢-1,2-恶唑-3-基)乙酸酯 环戊二烯并[d]咪唑-2,5(1H,3H)-二硫酮 环己羧酸,3-氨基-2-甲氧基-,甲基酯,(1S,2S,3S)- 溶剂黄93 溴化1-十六烷基-3-甲基咪唑 溴化1-十二烷基-2,3-二甲基咪唑 泰比培南酯中间体 泰比培南酯中间体 氨甲酸,[4,5-二氢-4-(碘甲基)-2-噻唑基]-,1,1-二甲基乙基酯(9CI) 氨基甲硫酸,[2-[[(2-羰基-1-咪唑烷基)硫代甲基]氨基]乙基]-,O-甲基酯 异噻唑,4,5-二氯-2,5-二氢-2-辛基- 希诺米啉 四氟硼酸二氢1,3-二(叔-丁基)-4,5--1H-咪唑正离子 四唑硝基紫 噻唑烷-2,4-二酮-2-缩氨基脲 噻唑丁炎酮 噻唑,4,5-二氢-4-(1-甲基乙基)-,(S)- 噁唑,4,5-二氢-4,4-二甲基-2-(5-甲基-2-呋喃基)- 噁唑,2-庚基-4,5-二氢- 咪唑烷基脲 吡嗪,2,3-二氢-5,6-二甲基-2-丙基- 叔-丁基3-羟基-1,4,6,7-四氢吡唑并[4,3-c]吡啶-5-羧酸酯 双吡唑啉酮